PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Prelude Therapeutics Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.39+0.13 (+3.99%)
Close on Oct 19, 2026
- Market cap
- $333.54M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$2.20 (+184.9%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Prelude Therapeutics Inc grew revenue 220.3% to $22.42M over the twelve months to Jun 30, 2026. Free cash flow was -$33.26M.
Revenue
$22.42M
+220.3% vs. a year earlier
Operating income
-$67.40M
TTM Q2 2026
Free cash flow
-$33.26M
TTM Q2 2026
EPS, diluted
-$0.74
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $333.54M
- P/E ratio
- –
- Price to sales
- 14.87
- Price to book
- 2.49
- Dividend yield
- –
- Free cash flow yield
- -9.97%
Fundamentals
- Revenue
- $22.42M
- Net income
- -$60.49M
- EPS, diluted
- -$0.74
- Free cash flow
- -$33.26M
- Book value per share
- $1.36
- Diluted shares
- 98M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$22.42M+220.3% YoY
Operating income
-$67.40M
Net income
-$60.49M
EPS, diluted
-$0.74
Free cash flow
-$33.26M
Reported periodTrailing twelve months